Abstract

Broadly-neutralizing antibodies (bNAbs) against HIV-1 Env can protect from infection. We characterize Ab1303 and Ab1573, heterologously-neutralizing CD4-binding site (CD4bs) antibodies, isolated from sequentially-immunized macaques. Ab1303/Ab1573 binding is observed only when Env trimers are not constrained in the closed, prefusion conformation. Fab-Env cryo-EM structures show that both antibodies recognize the CD4bs on Env trimer with an ‘occluded-open’ conformation between closed, as targeted by bNAbs, and fully-open, as recognized by CD4. The occluded-open Env trimer conformation includes outwardly-rotated gp120 subunits, but unlike CD4-bound Envs, does not exhibit V1V2 displacement, 4-stranded gp120 bridging sheet, or co-receptor binding site exposure. Inter-protomer distances within trimers measured by double electron-electron resonance spectroscopy suggest an equilibrium between occluded-open and closed Env conformations, consistent with Ab1303/Ab1573 binding stabilizing an existing conformation. Studies of Ab1303/Ab1573 demonstrate that CD4bs neutralizing antibodies that bind open Env trimers can be raised by immunization, thereby informing immunogen design and antibody therapeutic efforts.

Neutralizing antibodies (bNAbs) against HIV-1 are exclusively directed against the viral envelope protein (Env) and mainly target Env in a closed, prefusion state. Here, Yang et al. structurally characterize two heterologously-neutralizing CD4-binding site (CD4bs) antibodies isolated from sequentially immunized macaques, and show that these antibodies recognize the CD4bs on Env trimers in an „occluded-open‟ conformation between closed, as targeted by bNAbs, and fully-open, as recognized by CD4.

Details

Title
Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer
Author
Yang, Zhi 1 ; Dam, Kim-Marie A 1   VIAFID ORCID Logo  ; Bridges, Michael D 2 ; Hoffmann, Magnus A, G 1   VIAFID ORCID Logo  ; DeLaitsch, Andrew T 1   VIAFID ORCID Logo  ; Gristick, Harry B 1 ; Escolano Amelia 3 ; Gautam Rajeev 4 ; Martin, Malcolm A 4 ; Nussenzweig, Michel C 5 ; Hubbell, Wayne L 2 ; Bjorkman, Pamela J 1   VIAFID ORCID Logo 

 California Institute of Technology, Division of Biology and Biological Engineering, Pasadena, USA (GRID:grid.20861.3d) (ISNI:0000000107068890) 
 Jules Stein Eye Institute, University of California, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); University of California, Department of Chemistry and Biochemistry, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718) 
 The Rockefeller University, Laboratory of Molecular Immunology, New York, USA (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519) 
 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Laboratory of Molecular Microbiology, Bethesda, USA (GRID:grid.419681.3) (ISNI:0000 0001 2164 9667) 
 The Rockefeller University, Laboratory of Molecular Immunology, New York, USA (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519); The Rockefeller University, Howard Hughes Medical Institute, New York, USA (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2626455685
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.